Clinical Trials Browser

Phase 2/3 × Squamous Cell Carcinoma of Head and Neck × 30 days × Clear all

NCT05063552 2026-03-18

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01810913 2026-03-13

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06030440 2026-03-13

DIREKHT2

Phase 2/3 Recruiting

508 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06788990 2026-03-05

FORTIFI-HN01

Phase 2/3 Recruiting

650 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome